Literature DB >> 21927932

PET imaging of HER-2-positive tumours.

Laura Gilardi, Giovanni Paganelli.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21927932     DOI： 10.1007/s00259-011-1933-7

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN： 1619-7070            Impact factor:   9.236


× No keyword cloud information.
  16 in total

Review 1.  Emerging targeted therapies for breast cancer.

Authors:  Ricardo H Alvarez; Vicente Valero; Gabriel N Hortobagyi
Journal:  J Clin Oncol       Date:  2010-06-07       Impact factor: 44.544

2.  Engineered two-helix small proteins for molecular recognition.

Authors:  Jack M Webster; Rong Zhang; Sanjiv S Gambhir; Zhen Cheng; Faisal A Syud
Journal:  Chembiochem       Date:  2009-05-25       Impact factor: 3.164

3.  Integrating molecular profiling, histological type and other variables: defining the fingerprint of responsiveness to treatment.

Authors:  Giuseppe Viale
Journal:  Breast       Date:  2009-10       Impact factor: 4.380

Review 4.  Towards detecting the HER-2 receptor and metabolic changes induced by HER-2-targeted therapies using medical imaging.

Authors:  T A D Smith
Journal:  Br J Radiol       Date:  2010-08       Impact factor: 3.039

5.  Molecular imaging of HER2-expressing malignant tumors in breast cancer patients using synthetic 111In- or 68Ga-labeled affibody molecules.

Authors:  Richard P Baum; Vikas Prasad; Dirk Müller; Christiane Schuchardt; Anna Orlova; Anders Wennborg; Vladimir Tolmachev; Joachim Feldwisch
Journal:  J Nucl Med       Date:  2010-05-19       Impact factor: 10.057

Review 6.  The need to examine metastatic tissue at the time of progression of breast cancer: is re-biopsy a necessity or a luxury?

Authors:  Mustafa Khasraw; Edi Brogi; Andrew D Seidman
Journal:  Curr Oncol Rep       Date:  2011-02       Impact factor: 5.075

7.  American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.

Authors:  Antonio C Wolff; M Elizabeth H Hammond; Jared N Schwartz; Karen L Hagerty; D Craig Allred; Richard J Cote; Mitchell Dowsett; Patrick L Fitzgibbons; Wedad M Hanna; Amy Langer; Lisa M McShane; Soonmyung Paik; Mark D Pegram; Edith A Perez; Michael F Press; Anthony Rhodes; Catharine Sturgeon; Sheila E Taube; Raymond Tubbs; Gail H Vance; Marc van de Vijver; Thomas M Wheeler; Daniel F Hayes
Journal:  J Clin Oncol       Date:  2006-12-11       Impact factor: 44.544

Review 8.  Advances in targeting human epidermal growth factor receptor-2 signaling for cancer therapy.

Authors:  Funda Meric-Bernstam; Mien-Chie Hung
Journal:  Clin Cancer Res       Date:  2006-11-01       Impact factor: 12.531

Review 9.  Immunoscintigraphy as potential tool in the clinical evaluation of HER2/neu targeted therapy.

Authors:  Eli C F Dijkers; Elisabeth G E de Vries; Jos G W Kosterink; Adrienne H Brouwers; Marjolijn N Lub-de Hooge
Journal:  Curr Pharm Des       Date:  2008       Impact factor: 3.116

10.  Comparison of HER-2 overexpression in primary breast cancer and metastatic sites and its effect on biological targeting therapy of metastatic disease.

Authors:  J Zidan; I Dashkovsky; C Stayerman; W Basher; C Cozacov; A Hadary
Journal:  Br J Cancer       Date:  2005-09-05       Impact factor: 7.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.